Global Rucaparib API Market Research Report 2025

Publication ID:

PB501253303

Publication Date:

February 5, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Specialty Chemicals [2]

Manufacturing (Chemicals) [3]

Chemicals [4]

Description:

The global market for Rucaparib API was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Rucaparib API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Rucaparib API.
The Rucaparib API market size, estimations, and forecasts are provided in terms of output/shipments (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Rucaparib API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Rucaparib API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, production, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lepu Medical Technology
Teva API
Clovis Oncology
APExBIO Technology
Angle Bio Pharma
HUATENG PHARMA
Lonza
by Type
Purity 鈮�98%
Purity 鈮�99%
by Application
Ovarian Cancer
Prostate Cancer
Production by Region
North America
Europe
China
Japan
Consumption by Region
North America
U.S.
Canada
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Rest of Europe
Latin America, Middle East & Africa
Mexico
Brazil
Turkey
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Rucaparib API manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Production/output, value of Rucaparib API by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 4: Consumption of Rucaparib API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 5: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Rucaparib API Market Overview
1.1 Product Definition
1.2 Rucaparib API by Type
1.2.1 Global Rucaparib API Market Value Growth Rate Analysis by Type: 2024 VS 2031
1.2.2 Purity 鈮�98%
1.2.3 Purity 鈮�99%
1.3 Rucaparib API by Application
1.3.1 Global Rucaparib API Market Value Growth Rate Analysis by Application: 2024 VS 2031
1.3.2 Ovarian Cancer
1.3.3 Prostate Cancer
1.4 Global Market Growth Prospects
1.4.1 Global Rucaparib API Production Value Estimates and Forecasts (2020-2031)
1.4.2 Global Rucaparib API Production Capacity Estimates and Forecasts (2020-2031)
1.4.3 Global Rucaparib API Production Estimates and Forecasts (2020-2031)
1.4.4 Global Rucaparib API Market Average Price Estimates and Forecasts (2020-2031)
1.5 Assumptions and Limitations
2 Market Competition by Manufacturers
2.1 Global Rucaparib API Production Market Share by Manufacturers (2020-2025)
2.2 Global Rucaparib API Production Value Market Share by Manufacturers (2020-2025)
2.3 Global Key Players of Rucaparib API, Industry Ranking, 2023 VS 2024
2.4 Global Rucaparib API Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.5 Global Rucaparib API Average Price by Manufacturers (2020-2025)
2.6 Global Key Manufacturers of Rucaparib API, Manufacturing Base Distribution and Headquarters
2.7 Global Key Manufacturers of Rucaparib API, Product Offered and Application
2.8 Global Key Manufacturers of Rucaparib API, Date of Enter into This Industry
2.9 Rucaparib API Market Competitive Situation and Trends
2.9.1 Rucaparib API Market Concentration Rate
2.9.2 Global 5 and 10 Largest Rucaparib API Players Market Share by Revenue
2.10 Mergers & Acquisitions, Expansion
3 Rucaparib API Production by Region
3.1 Global Rucaparib API Production Value Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.2 Global Rucaparib API Production Value by Region (2020-2031)
3.2.1 Global Rucaparib API Production Value by Region (2020-2025)
3.2.2 Global Forecasted Production Value of Rucaparib API by Region (2026-2031)
3.3 Global Rucaparib API Production Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
3.4 Global Rucaparib API Production Volume by Region (2020-2031)
3.4.1 Global Rucaparib API Production by Region (2020-2025)
3.4.2 Global Forecasted Production of Rucaparib API by Region (2026-2031)
3.5 Global Rucaparib API Market Price Analysis by Region (2020-2025)
3.6 Global Rucaparib API Production and Value, Year-over-Year Growth
3.6.1 North America Rucaparib API Production Value Estimates and Forecasts (2020-2031)
3.6.2 Europe Rucaparib API Production Value Estimates and Forecasts (2020-2031)
3.6.3 China Rucaparib API Production Value Estimates and Forecasts (2020-2031)
3.6.4 Japan Rucaparib API Production Value Estimates and Forecasts (2020-2031)
4 Rucaparib API Consumption by Region
4.1 Global Rucaparib API Consumption Estimates and Forecasts by Region: 2020 VS 2024 VS 2031
4.2 Global Rucaparib API Consumption by Region (2020-2031)
4.2.1 Global Rucaparib API Consumption by Region (2020-2025)
4.2.2 Global Rucaparib API Forecasted Consumption by Region (2026-2031)
4.3 North America
4.3.1 North America Rucaparib API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.3.2 North America Rucaparib API Consumption by Country (2020-2031)
4.3.3 U.S.
4.3.4 Canada
4.4 Europe
4.4.1 Europe Rucaparib API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.4.2 Europe Rucaparib API Consumption by Country (2020-2031)
4.4.3 Germany
4.4.4 France
4.4.5 U.K.
4.4.6 Italy
4.4.7 Russia
4.5 Asia Pacific
4.5.1 Asia Pacific Rucaparib API Consumption Growth Rate by Region: 2020 VS 2024 VS 2031
4.5.2 Asia Pacific Rucaparib API Consumption by Region (2020-2031)
4.5.3 China
4.5.4 Japan
4.5.5 South Korea
4.5.6 China Taiwan
4.5.7 Southeast Asia
4.5.8 India
4.6 Latin America, Middle East & Africa
4.6.1 Latin America, Middle East & Africa Rucaparib API Consumption Growth Rate by Country: 2020 VS 2024 VS 2031
4.6.2 Latin America, Middle East & Africa Rucaparib API Consumption by Country (2020-2031)
4.6.3 Mexico
4.6.4 Brazil
4.6.5 Turkey
4.6.6 GCC Countries
5 Segment by Type
5.1 Global Rucaparib API Production by Type (2020-2031)
5.1.1 Global Rucaparib API Production by Type (2020-2025)
5.1.2 Global Rucaparib API Production by Type (2026-2031)
5.1.3 Global Rucaparib API Production Market Share by Type (2020-2031)
5.2 Global Rucaparib API Production Value by Type (2020-2031)
5.2.1 Global Rucaparib API Production Value by Type (2020-2025)
5.2.2 Global Rucaparib API Production Value by Type (2026-2031)
5.2.3 Global Rucaparib API Production Value Market Share by Type (2020-2031)
5.3 Global Rucaparib API Price by Type (2020-2031)
6 Segment by Application
6.1 Global Rucaparib API Production by Application (2020-2031)
6.1.1 Global Rucaparib API Production by Application (2020-2025)
6.1.2 Global Rucaparib API Production by Application (2026-2031)
6.1.3 Global Rucaparib API Production Market Share by Application (2020-2031)
6.2 Global Rucaparib API Production Value by Application (2020-2031)
6.2.1 Global Rucaparib API Production Value by Application (2020-2025)
6.2.2 Global Rucaparib API Production Value by Application (2026-2031)
6.2.3 Global Rucaparib API Production Value Market Share by Application (2020-2031)
6.3 Global Rucaparib API Price by Application (2020-2031)
7 Key Companies Profiled
7.1 Lepu Medical Technology
7.1.1 Lepu Medical Technology Rucaparib API Company Information
7.1.2 Lepu Medical Technology Rucaparib API Product Portfolio
7.1.3 Lepu Medical Technology Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.1.4 Lepu Medical Technology Main Business and Markets Served
7.1.5 Lepu Medical Technology Recent Developments/Updates
7.2 Teva API
7.2.1 Teva API Rucaparib API Company Information
7.2.2 Teva API Rucaparib API Product Portfolio
7.2.3 Teva API Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.2.4 Teva API Main Business and Markets Served
7.2.5 Teva API Recent Developments/Updates
7.3 Clovis Oncology
7.3.1 Clovis Oncology Rucaparib API Company Information
7.3.2 Clovis Oncology Rucaparib API Product Portfolio
7.3.3 Clovis Oncology Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.3.4 Clovis Oncology Main Business and Markets Served
7.3.5 Clovis Oncology Recent Developments/Updates
7.4 APExBIO Technology
7.4.1 APExBIO Technology Rucaparib API Company Information
7.4.2 APExBIO Technology Rucaparib API Product Portfolio
7.4.3 APExBIO Technology Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.4.4 APExBIO Technology Main Business and Markets Served
7.4.5 APExBIO Technology Recent Developments/Updates
7.5 Angle Bio Pharma
7.5.1 Angle Bio Pharma Rucaparib API Company Information
7.5.2 Angle Bio Pharma Rucaparib API Product Portfolio
7.5.3 Angle Bio Pharma Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.5.4 Angle Bio Pharma Main Business and Markets Served
7.5.5 Angle Bio Pharma Recent Developments/Updates
7.6 HUATENG PHARMA
7.6.1 HUATENG PHARMA Rucaparib API Company Information
7.6.2 HUATENG PHARMA Rucaparib API Product Portfolio
7.6.3 HUATENG PHARMA Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.6.4 HUATENG PHARMA Main Business and Markets Served
7.6.5 HUATENG PHARMA Recent Developments/Updates
7.7 Lonza
7.7.1 Lonza Rucaparib API Company Information
7.7.2 Lonza Rucaparib API Product Portfolio
7.7.3 Lonza Rucaparib API Production, Value, Price and Gross Margin (2020-2025)
7.7.4 Lonza Main Business and Markets Served
7.7.5 Lonza Recent Developments/Updates
8 Industry Chain and Sales Channels Analysis
8.1 Rucaparib API Industry Chain Analysis
8.2 Rucaparib API Raw Material Supply Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.3 Rucaparib API Production Mode & Process Analysis
8.4 Rucaparib API Sales and Marketing
8.4.1 Rucaparib API Sales Channels
8.4.2 Rucaparib API Distributors
8.5 Rucaparib API Customer Analysis
9 Rucaparib API Market Dynamics
9.1 Rucaparib API Industry Trends
9.2 Rucaparib API Market Drivers
9.3 Rucaparib API Market Challenges
9.4 Rucaparib API Market Restraints
10 Research Findings and Conclusion
11 Methodology and Data Source
11.1 Methodology/Research Approach
11.1.1 Research Programs/Design
11.1.2 Market Size Estimation
11.1.3 Market Breakdown and Data Triangulation
11.2 Data Source
11.2.1 Secondary Sources
11.2.2 Primary Sources
11.3 Author List
11.4 Disclaimer

Companies Mentioned:

Lepu Medical Technology
Teva API
Clovis Oncology
APExBIO Technology
Angle Bio Pharma
HUATENG PHARMA
Lonza

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂